DISCOUNT ZERTIFIKAT - ROCHE GS Stock

Certificat

DE000VU4DP94

Delayed Deutsche Boerse AG 13:40:20 2024-06-20 EDT
241.1 EUR -0.38% Intraday chart for DISCOUNT ZERTIFIKAT - ROCHE GS
Current month+4.11%
1 month+4.50%
Date Price Change
24-06-20 241.1 -0.38%
24-06-19 242 -0.09%
24-06-18 242.2 +0.60%
24-06-17 240.8 -0.30%
24-06-14 241.5 +0.91%

Delayed Quote Deutsche Boerse AG

Last update June 20, 2024 at 01:40 pm

More quotes

Static data

Product typeDiscount Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VU4DP9
ISINDE000VU4DP94
Date issued 2023-03-07
Maturity Today (1 Days)
Parity 1 : 1
Emission price 216.6
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 242.4
Lowest since issue 217.3

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.22%
Consensus